Sergio Giralt

Active 1993–2025

330
Papers
55,289
Citations
125
h-index
316
i10-index

Citations

Citations per year for Sergio Giralt1948: 2 citations1990: 1 citations1991: 1 citations1992: 1 citations1994: 5 citations1995: 16 citations1996: 30 citations1997: 33 citations1998: 51 citations1999: 92 citations2000: 137 citations2001: 148 citations2002: 224 citations2003: 297 citations2004: 184 citations2005: 211 citations2006: 205 citations2007: 231 citations2008: 240 citations2009: 222 citations2010: 315 citations2011: 286 citations2012: 293 citations2013: 330 citations2014: 289 citations2015: 344 citations2016: 348 citations2017: 360 citations2018: 360 citations2019: 1,314 citations2020: 1,701 citations2021: 1,685 citations2022: 1,283 citations2023: 1,139 citations2024: 1,919 citations2025: 927 citations2026: 27 citations1949–1989: no citations, so these years are not shown1993: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 5,642 citing papers, 29% of this breakdownGermany: 1,424 citing papers, 7.3% of this breakdownChina: 1,181 citing papers, 6.1% of this breakdownItaly: 1,129 citing papers, 5.8% of this breakdownUnited Kingdom: 1,076 citing papers, 5.5% of this breakdownFrance: 1,044 citing papers, 5.4% of this breakdownSpain: 840 citing papers, 4.3% of this breakdownNetherlands: 684 citing papers, 3.5% of this breakdownCanada: 615 citing papers, 3.2% of this breakdownJapan: 436 citing papers, 2.2% of this breakdownAustralia: 425 citing papers, 2.2% of this breakdownSwitzerland: 407 citing papers, 2.1% of this breakdown
0%29%Other 23.4%

Fields

  • Medicine83.1%
  • Biochemistry, Genetics and Molecular Biology10.4%
  • Immunology and Microbiology4.6%
  • Engineering0.4%
  • Nursing0.2%
  • Agricultural and Biological Sciences0.2%
  • Other1.1%

Topics

  • Hematopoietic Stem Cell Transplantation9.4%
  • CAR-T cell therapy research8.2%
  • Multiple Myeloma Research and Treatments6.5%
  • Acute Myeloid Leukemia Research5.3%
  • Immune Cell Function and Interaction3.6%
  • Acute Lymphoblastic Leukemia research3%
  • Other64%

Coauthors

All papers

Open in search
  1. Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma

    Authors: , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2023 cited by 705

  2. Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Michel Sadelain, Renier J. Brentjens - Science Translational Medicine 2014 cited by 2,497

  3. GPRC5D-Targeted CAR T Cells for Myeloma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Ahmet Doǧan, Ola Landgren, Sergio Giralt, Jae H. Park, Saad Z. Usmani, Isabelle Rivière, Renier J. Brentjens, Eric L. Smith - New England Journal of Medicine 2022 cited by 384

  4. Microbiota as Predictor of Mortality in Allogeneic Hematopoietic-Cell Transplantation

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Nerea Castillo Flores, Ana Alarcón Tomás, Richard J. Lin, Lucrecia Yáñez, Gunjan L. Shah, Christina Cho, Michael Scordo, Ioannis Politikos, Kasumi Hayasaka, Yuta Hasegawa, Boglarka Gyurkocza, Doris M. Ponce, Juliet N. Barker, Miguel‐Angel Perales, Sergio Giralt, Robert R. Jenq, Takanori Teshima, Nelson J. Chao, Ernst Holler, João B. Xavier, Eric G. Pamer, Marcel R.M. van den Brink - New England Journal of Medicine 2020 cited by 739

  5. Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Daniel J. Landsburg, James N. Gerson, Jakub Svoboda, Justin R. Cross, Elise A. Chong, Sergio Giralt, Saar Gill, Isabelle Rivière, David L. Porter, Stephen J. Schuster, Michel Sadelain, Noelle V. Frey, Renier J. Brentjens, Carl H. June, Eric G. Pamer, Jonathan U. Peled, Andrea Facciabene, Marcel R.M. van den Brink, Marco Ruella - Nature Medicine 2022 cited by 309

  6. Defining the Intensity of Conditioning Regimens: Working Definitions

    Authors: , , , , , , , , , , , , , - Biology of Blood and Marrow Transplantation 2009 cited by 1,797

  7. Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Adam D. Cohen, Thomas H. Openshaw, Marcelo C. Pasquini, Sergio Giralt, Jonathan L. Kaufman, Andrew J. Yee, Emma C. Scott, Pallawi Torka, Amy Foley, Mariateresa Fulciniti, Kyle Hebert, Mehmet Samur, Kelly Masone, Michelle E. Maglio, Andrea A. Zeytoonjian, Omar Nadeem, Robert Schlossman, Jacob P. Laubach, Claudia E. Paba‐Prada, Irene M. Ghobrial, Aurore Perrot, Philippe Moreau, Hervé Avet‐Loiseau, Michel Attal, Kenneth C. Anderson, Nikhil C. Munshi - New England Journal of Medicine 2022 cited by 463

  8. The effects of intestinal tract bacterial diversity on mortality following allogeneic hematopoietic stem cell transplantation

    Authors: , , , , , , , , , , , , , , - Blood 2014 cited by 880

  9. Lactose drives Enterococcus expansion to promote graft-versus-host disease

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Anthony D. Sung, Daigo Hashimoto, Christof Scheid, João B. Xavier, Julia A. Messina, Kristi Romero, M. Lew, Amy Bush, Lauren Bohannon, Kasumi Hayasaka, Yuta Hasegawa, Maria J. G. T. Vehreschild, Justin R. Cross, Doris M. Ponce, Miguel‐Angel Perales, Sergio Giralt, Robert R. Jenq, Takanori Teshima, Ernst Holler, Nelson J. Chao, Eric G. Pamer, Jonathan U. Peled, Marcel R.M. van den Brink - Science 2019 cited by 369

  10. Impact of Conditioning Intensity of Allogeneic Transplantation for Acute Myeloid Leukemia With Genomic Evidence of Residual Disease

    Authors: , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2019 cited by 442

  11. Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies

    Authors: , , , , , , , , , , , , , , , , , , , , , , , - Blood Advances 2020 cited by 264

  12. International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Baldeep Wirk, Matthew T. Drake, Michèle Cavo, Juan José Lahuerta, Suzanne Lentzsch - The Lancet Oncology 2019 cited by 496

  13. Intestinal Blautia Is Associated with Reduced Death from Graft-versus-Host Disease

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , - Biology of Blood and Marrow Transplantation 2015 cited by 762

  14. Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes

    Authors: , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2017 cited by 666

  15. Modified EASIX predicts severe cytokine release syndrome and neurotoxicity after chimeric antigen receptor T cells

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , - Blood Advances 2021 cited by 198

  16. Reconstitution of the gut microbiota of antibiotic-treated patients by autologous fecal microbiota transplant

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Eric G. Pamer, João B. Xavier - Science Translational Medicine 2018 cited by 373

  17. Reduced-Intensity Conditioning Regimen Workshop: Defining the Dose Spectrum. Report of a Workshop Convened by the Center for International Blood and Marrow Transplant Research

    Authors: , , , , , , - Biology of Blood and Marrow Transplantation 2009 cited by 901

  18. Randomized Phase III BMT CTN Trial of Calcineurin Inhibitor–Free Chronic Graft-Versus-Host Disease Interventions in Myeloablative Hematopoietic Cell Transplantation for Hematologic Malignancies

    Authors: , , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2021 cited by 168

  19. Interventions and outcomes of patients with multiple myeloma receiving salvage therapy after BCMA-directed CAR T therapy

    Authors: , , , , , , , , , , , , , , , , , , , , , , - Blood 2022 cited by 103

  20. Off-the-shelf EBV-specific T cell immunotherapy for rituximab-refractory EBV-associated lymphoma following transplantation

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Susan H. Hsu, Aisha Hasan, Richard J. O’Reilly - Journal of Clinical Investigation 2019 cited by 229

  21. Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Blood 2017 cited by 376

  22. Outcomes of first therapy after CD19-CAR-T treatment failure in large B-cell lymphoma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Abraham Avigdor, Miguel‐Angel Perales, Roni Shouval - Leukemia 2022 cited by 102

  23. Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203)

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Daniel J. Weisdorf, Juan Wu, Marcelo C. Pasquini, John Koreth - The Lancet Haematology 2019 cited by 281

  24. Indications for Hematopoietic Cell Transplantation and Immune Effector Cell Therapy: Guidelines from the American Society for Transplantation and Cellular Therapy

    Authors: , , , , , , , , , , , , , , , - Biology of Blood and Marrow Transplantation 2020 cited by 274